Sunmax Biotechnology Co., Ltd. (TPEX:4728)
415.50
-5.50 (-1.31%)
Sep 19, 2025, 1:30 PM CST
Sunmax Biotechnology Revenue
Sunmax Biotechnology had revenue of 460.13M TWD in the quarter ending June 30, 2025, with 1.42% growth. This brings the company's revenue in the last twelve months to 1.95B, up 10.87% year-over-year. In the year 2024, Sunmax Biotechnology had annual revenue of 1.82B with 7.64% growth.
Revenue (ttm)
1.95B
Revenue Growth
+10.87%
P/S Ratio
11.60
Revenue / Employee
n/a
Employees
n/a
Market Cap
22.63B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.82B | 129.03M | 7.64% |
Dec 31, 2023 | 1.69B | 288.91M | 20.64% |
Dec 31, 2022 | 1.40B | 364.42M | 35.19% |
Dec 31, 2021 | 1.04B | 179.81M | 21.01% |
Dec 31, 2020 | 855.85M | 261.71M | 44.05% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Caliway Biopharmaceuticals | 44.83M |
PharmaEssentia | 12.63B |
Bora Pharmaceuticals Co., LTD. | 21.32B |
Lumosa Therapeutics | 37.25M |
Lotus Pharmaceutical | 19.12B |
Oneness Biotech | 112.57M |
Polaris Group | 64.02M |
Center Laboratories | 1.60B |